Successful treatment of bronchiolitis obliterans organizing pneumonia associated with polymyositis with a steroid inhaler and low-dose cyclophosphamide.
- Author:
Chan Young YUN
1
;
Ran SONG
;
Ki won MOON
;
Yun Jong LEE
;
Yeong Wook SONG
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. ysong@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Polymyositis;
Bronchiolitis obliterans organizing pneumonia;
Steroid-induced myopathy;
Steroid inhaler
- MeSH:
Azathioprine;
Bronchiolitis;
Bronchiolitis Obliterans;
Connective Tissue Diseases;
Cryptogenic Organizing Pneumonia;
Cyclophosphamide;
Cyclosporine;
Humans;
Immunosuppressive Agents;
Lung Diseases, Interstitial;
Methotrexate;
Muscle, Skeletal;
Muscular Diseases;
Nebulizers and Vaporizers;
Opportunistic Infections;
Polymyositis;
Prognosis;
Psychotic Disorders
- From:Korean Journal of Medicine
2009;77(5):654-658
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Polymyositis is an inflammatory connective tissue disease involving, predominantly, skeletal muscle. Occasionally, it is complicated by serious interstitial pneumonia. The presence of interstitial pneumonia affects the prognosis and contributes substantially to the morbidity and mortality. Although the treatment recommendations for interstitial pneumonia in polymyositis are still not optimal, high-dose steroid or immunosuppressive agents such as methotrexate, azathioprine, cyclosporine A, or cyclophosphamide alone or in combination are effective in myositis-associated interstitial pneumonia in many cases. Nevertheless, the relative frequency of complications, such as opportunistic infection, steroid-induced myopathy, and steroid psychosis, limits the use of high-dose steroid or immunosuppressive regimens. Here, we describe our experience of combination treatment with a steroid inhaler and low-dose cyclophosphamide in a patient with bronchiolitis obliterans organizing pneumonia associated with polymyositis who developed steroid-induced myopathy during initial high-dose steroid and cyclosporine A treatment.
